Natasha Rekhtman
Overview
Explore the profile of Natasha Rekhtman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
17145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Febres-Aldana C, Vojnic M, Odintsov I, Zhang T, Cheng R, Beach C, et al.
Cancer Discov
. 2025 Feb;
PMID: 39965191
MET fusions (MET-Fs) are oncogenic drivers that remain poorly characterized. Analysis of 56 MET-F-positive tumors from an institutional cohort of 91,119 patients (79,864 DNA-seq plus 11,255 RNA-seq) uncovered two forms...
2.
Cooper A, Arfe A, Ricciuti B, Gagne A, Sholl L, Di Federico A, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100759.
PMID: 39802817
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown. Methods: We collected clinical,...
3.
Fanaroff R, Yang S, Tan K, Adusumilli P, Bodd F, Bowman A, et al.
Mod Pathol
. 2025 Jan;
38(5):100706.
PMID: 39788204
Histologic features, including architectural patterns, cytologic features, and 2021 World Health Organization nuclear grade have been shown to have prognostic significance in epithelioid diffuse pleural mesothelioma (DPM). Biphasic and sarcomatoid...
4.
Kim D, Vanderbilt C, Yang S, Nandakumar S, Nafa K, Feratovic R, et al.
Nat Commun
. 2025 Jan;
16(1):116.
PMID: 39747849
Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally invasive procedures....
5.
Cooper A, Rekhtman N, Baine M, Thomas M, Lynch A, Gentzler R
JTO Clin Res Rep
. 2024 Dec;
5(12):100750.
PMID: 39619276
Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy...
6.
Febres-Aldana C, Elsayad M, Saliba M, Bhanot U, Ntiamoah P, Takeyama A, et al.
Mod Pathol
. 2024 Nov;
38(3):100674.
PMID: 39613231
The diagnosis and treatment of sinonasal small round epithelial/neuroepithelial malignancies depend on the expression of conventional neuroendocrine markers (NEMs), such as synaptophysin, chromogranin A, INSM1, and CD56/NCAM1. However, these tumors...
7.
Chou T, Dacic S, Wistuba I, Beasley M, Berezowska S, Chang Y, et al.
J Thorac Oncol
. 2024 Nov;
20(3):311-330.
PMID: 39579981
Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging...
8.
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, et al.
Cell Rep Med
. 2024 Oct;
5(10):101777.
PMID: 39413736
Approximately 50% of patients with surgically resected early-stage lung cancer develop distant metastasis. At present, there is no in vivo metastasis model to investigate the biology of human lung cancer...
9.
Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegele C, Sexton-Oates A, et al.
J Clin Oncol
. 2024 Sep;
43(2):214-225.
PMID: 39348606
Purpose: The clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical...
10.
Xu B, Baine M, Jungbluth A, Alabkaa A, Serrette R, Roy D, et al.
J Clin Endocrinol Metab
. 2024 Sep;
PMID: 39324657
Purpose: Seizure-related 6 homolog (SEZ6) is a cDNA that strongly associated with neuroendocrine differentiation. Recently, SEZ6 expression was found in a subset of small cell lung carcinoma (SCLC). Furthermore, ABBV-011,...